EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Genetic differences between primary colorectal cancer and its paired synchronous and metachronous metastases

Marie Rajtmajerova iD, Filip Ambrozkiewicz iD, Viktor Hlavac iD, Andriy Trailin iD, Lenka Cervenkova, Jan Bruha, Simona Susova, Pavel Soucek, Pavel Vodicka, Ludmila Vodickova, Ondrej Kubecek, Stanislav Filip und 5 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Marie Rajtmajerova und 16 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Translational Cancer Genomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Liver Neoplasms, Neoplasms, Second Primary, Neoplasms, Multiple Primary. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Grantová Agentura České Republiky, Grant Agency of the Czech Republic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As the second most deadly cancerous disease worldwide, colorectal cancer (CRC) stands in the center of scientific interest in hope to develop novel approaches for precise diagnostics and prognosis determination. Metastatic disease remains the main cause of CRC mortality. To investigate the underlying genetic differences between CRC patients with synchronous and metachronous liver metastases, we performed whole‐exome sequencing of 210 patient samples using formalin‐fixed paraffin‐embedded samples from primary tumors and the paired liver metastatic tissue. The analyses included types and levels of mutations and copy number variation. APC and TP53 were the most commonly mutated genes in all samples with differing frequency between primary CRC (both 50%) and its metachronous metastasis (both 64%). While MPDZ gene mutations were restricted to primary tumors that developed metachronous metastases only, mutations in VCAN , MTCL1 , MDN1 , SHROOM2, SPEG , and GLI2 were more prevalent in primary tumors giving rise to synchronous metastases. FBN1 mutations were unique to synchronous liver metastatic tissue. Analysis of genetic interactions revealed different associations between mutated genes in patients with tumors of different chronicity, including driver genes such as TP53 , which was associated with APC in synchronous patients, while in primary tumors with metachronous metastases it co‐occurs with mutations in NBPF11 and PRAMEF15, respectively. The results suggest that distinct tumor progression pathways account for different chronicity outcomes further affecting patients' survival. However, larger studies are needed incorporating transcriptomic and epigenomic data to shed further light on the mechanistic chain from mutations to downstream gene expression regulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsLiver NeoplasmsNeoplasms, Second PrimaryNeoplasms, Multiple PrimaryHumansFemaleMaleMutationMiddle AgedExome SequencingAgedDNA Copy Number VariationsAdultPrognosis

Stichwörter der Autor:innen

WEScolorectal cancermetachronous liver metastasissynchronous liver metastasiswhole‐exome sequencing

Autor:innen und Institutionen

  • Laboratory of Translational Cancer Genomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
  • Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
  • Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic.
  • Laboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
  • Department of Surgery, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
  • Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic.

ORCID-Profile: Marie Rajtmajerova, Filip Ambrozkiewicz, Viktor Hlavac, Andriy Trailin, Frantisek Zitricky

Förderung

  • Grantová Agentura České Republiky
  • Grant Agency of the Czech Republic

Zitieren

APA

Rajtmajerova, M., Ambrozkiewicz, F., Hlavac, V., Trailin, A., Cervenkova, L., Bruha, J., Susova, S., Soucek, P., Vodicka, P., Vodickova, L., Kubecek, O., Filip, S., Mallela, V. R., Ye, W., Zitricky, F., Liska, V., & Hemminki, K. (2026). Genetic differences between primary colorectal cancer and its paired synchronous and metachronous metastases. International Journal of Cancer. https://doi.org/10.1002/ijc.70116

Vancouver

Rajtmajerova M, Ambrozkiewicz F, Hlavac V, Trailin A, Cervenkova L, Bruha J, et al. Genetic differences between primary colorectal cancer and its paired synchronous and metachronous metastases. International Journal of Cancer. 2026. doi:10.1002/ijc.70116

BibTeX
@article{Rajtmajerova2026,
  author = {Rajtmajerova, Marie and Ambrozkiewicz, Filip and Hlavac, Viktor and Trailin, Andriy and Cervenkova, Lenka and Bruha, Jan and Susova, Simona and Soucek, Pavel and Vodicka, Pavel and Vodickova, Ludmila and Kubecek, Ondrej and Filip, Stanislav and Mallela, Venkata R and Ye, Wenjing and Zitricky, Frantisek and Liska, Vaclav and Hemminki, Kari},
  title = {Genetic differences between primary colorectal cancer and its paired synchronous and metachronous metastases},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70116}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche